



How to reduce low value care?

The pragmatic "Choosing Wisely" approach of the French Geriatric Society

Pr Aline Corvol; G Gernigon, PharmD; Dr Pascal Jarno





 An initiative of the American Board of Internal Medicine Foundation (2012)

"Les:













An initiative of NPS MedicineWise



Sobria Rispettosa Giusta





An initiative of the ABIM Foundation





Klug entscheiden



CHOOSING WISELY WALES
DEWIS DOETH CYMRU








Principles

- Appropriateness drives quality of care
- Appropriateness is a professional challenge for healthcare workers
- Appropriateness is achieved through conversation with patients



Do you really need that medical test or treatment? The answer may be no.



Medical tests and

when you really n are times when X painkillers may b get them when th

Wisely



5 QUESTIONS to Ask Your Doctor Before You Get Any Test, Treatment, or Procedure

www.choosingwisely.org/patient-resources

- Do I really need this test or procedure?
- What are the risks and side effects?
- Are there simpler, safer options?
- What happens if I don't do anything?
- How much does it cost, and will my insurance pay for it?

© 2016 Consumer Reports











smarter medicine

Choosing Wisely Switzerland





5 recommandations of the French Geriatric Society


- Do not prescribe antipsychotics for behavioral and psychological symptoms of dementia (or only as a last resort)
- 2. Discontinue long-term benzodiazepine prescriptions
- Discontinue long-term treatment of Proton Pump Inhibitor if no indication persist
- 4. Do not prescribe urinalysis if there is no clinical urinary symptoms
- 5. Share decision making



Tool Box


Support de formation





Vidéo personne de confiance

€



Alprazolam (Xanax®)

Bromazepam (Lexomil®)

Clonazepam (Rivotril®)

Clorazepate (Tranxène®)

Lorazepam (Temesta®)

Loflazepate d'ethyle (Victan®)

Diazepam (Valium®)

SI J'ARRETE, J'AI :

- 1 médicament en moins à prendre par jour
- Une diminution du risque d'effets néfastes à long terme :



Inevium®

lexium control

et génériques

et génériques









- Une diminution des interactions avec d'autres médicaments (ex citalopram (Seropram® et génériques), clopidogrel (Plavix® et génériques))
- Une diminution du risque d'addiction au traitement

MAIS JE PEUX RENCONTRER CES EFFETS TEMPORAIRES :

- Possible augmentation de l'acidité de l'estomac à l'arrêt
 - → peut être SOULAGÉ en suivant des règles simples (voir devant)
- Possible sensation de manque à l'arrêt du traitement
- → Ces effets sont temporaires, ils vont disparaître rapidement.
- → VOTRE TRAITEMENT PEUT ÊTRE ARRÊTÉ PROGRESSIVEMENT AFIN DE LIMITER CES EFFETS.

LES IPP. CE N'EST PAS POUR L'ÉTERNITÉ





A retrouver sur le site internet : http://www.omedit-centre.f

2025





2014 FHF solicitation

first draft of reco (working group) 2016
First
Regional
campaign
clinical audit

2018
2d draft
reco
and validation
by a vote

2019
2d campaign
Clinical audit
(2 regions)


STOP t Covid 19 Scientific valorisation

2020-2021

3rd draft of reco + Toolbox

National campaign of clinical audits 2025

Creation of the French Deprescription Network





- √ 9 regions / 13
- √ 205 facilities
- √ 431 services
- 35% Long Term Care Facilities



Our approach on 3 pillars



- Choice of reco and selection of tools
- Regional level of dissemination through local champions
- Strong involvement of patient representatives
 - wrote one recommendation to promote shared decision making)
 - Evaluate It
 - Communicate
- Support for a quality and safety team in each participating region
 - Creating a national dynamic relies on champions, not funding.



Lessons



- Ensure a national representation of the working group
- Promote close communication within the scientific society.
- Involve different professions (pharmacists, nurses...)
- Identify support structures that allow independence
- Join the international "choosing Wisely" group



What next?



- Create a French Deprescription Network
- Bring together other scientific societies
- Find a financial model...





WWW.EHMA.ORG WWW.EHMACONFERENCE.ORG▼